Exam 4 Lesson 42 Flashcards

1
Q

How are cancers classified?

A

Based on tissue of origin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

carcinoma

A

Cancers arising from epithelial cells (most common)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

sarcomas

A

Cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

leukemias

A

Cancer that starts in blood-forming tissue such as the bone marrow and causes large numbers of abnormal blood cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lymphomas and myeloma

A

Cancers that begin in the cells of the immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

melanomas

A

Arise from the cells that produce the dark pigment in skin, hair

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

carcinogens

A

Substances that cause DNA mutations that cause cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Non- hereditary cancer

A

Somatic mutations cause most cancers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hereditary cancer

A

Germline mutations , rare (~5% of cancers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What kind of disease is cancer?

A

A genetic disease. Caused by gene mutations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Where do most cancers originate?

A

From a single aberrant cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What kind of mutations cause cancer?

A

cancer is caused by a progressive accumulation of random mutations in a single lineage of cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

clonal evolution theory

A

Accidental production of mutant cell
Cell proliferates and there are two mutations
Cell proliferates and there are three mutations
Can lead to dangerous cell proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the two kinds of mutation events?

A

Genetic change and epigenetic change

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the two kinds of genetic changes?

A

Small scale and large scale

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Small scale genetic changes

A

A small gene in one or a few nucleotides; point mutation, insertion, deletion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Large scale genetic changes

A

In chromosomal structure; duplication, amplification, deletion, insertion, inversion, translocation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Epigenetic change

A
Histone modification (heterochromatin pathway; not inherited);
DNA methylation (an inherited pattern of methylation of C nucleotides in CpG sequence)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is Gleevec?

A

A drug that targets a protein kinase that promotes development of leukemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are oncogenes?

A

They have a gain-of-function mutation. They produce overactive proteins that drive the cell cycle or contribute to some other aspect of the cancer process.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are tumor suppressor genes.

A

They suffer a loss-of-function mutation. The loss of both copies of the normal gene leads to cancer. Loss of gene activity may come from a genetic change or an epigenetic change.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What causes loss of gene activity?

A

A genetic change or an epigenetic change

23
Q

tumorigenesis

A

Evolution of a normal cell into a tumor cell. A process by which normal cells are transformed into cancer cells.

24
Q

Invasion/metastasis

A

Evolution of benign into a malignant cancer cell. Cancer cells break loose, enter blood or lymphatic vessels, and form secondary tumors at other sites in body.

25
Q

Six proposed hallmarks of cancer

A
  1. Self- sufficiency in growth signals
  2. Insensitivity to anti-growth signals
  3. Evading apoptosis
  4. Tissue invasion and metastasis
  5. Limitless replicative potential
  6. Sustained angiogenesis
26
Q

What does cell proliferation require?

A
  1. Progression through the cell cycle

2. Cell growth

27
Q

What do normal cells require for proliferation?

A

Signals in the form of cytokines, ECM components, and cell-cell interactions.

28
Q

How do cancer cells proliferate?

A

They generate their own cell proliferation signals (mutagens, growth factors) or they recruit nearby stromal cells, causing them to release growth factors.

29
Q

proto-oncogenes

A

Receptors for mutagens or growth factors that may be unregulated. Downstream signaling molecules that may be unregulated like mutant form of Ras, mTOR, or Akt.

30
Q

What loss of function mutations promote proliferation pathways?

A

Loss of function mutations in Rb and PTEN

31
Q

What do anti-proliferative and anti-growth signals usually block?

A

The inactivation of Rb

32
Q

What happens if Rb is active?

A

It inhibits E2F and expression of S-phase genes

33
Q

How are cancer cells insensitive to anti-growth or antiproliferation signals?

A

They may downregulate receptors for anti-proliferative signals, have loss-of-function mutations in Cdk inhibitors or loss of function mutations in Rb

34
Q

What is role of p16, or p15INK4?

A

It inhibits CDk4 from binding to cycling D, inhibiting the complex

35
Q

What is role of apoptosis?

A

It maintains constant cell number and eliminates cells that have become abnormal because of genetic mutations or other stresses.

36
Q

What does p53 protein do in response to DA damage and stress?

A
  1. Controls cell cycle arrest

2. Controls apoptosis

37
Q

What does p53 bind to?

A

It binds to regulatory region of p21 gene. p21 is a Cdk inhibitor protein.

38
Q

Why does FAK interact with growth factor receptors?

A

To control the ERK/MAPK pathway in regulation of cell proliferation.

39
Q

Do animal stem cells need to attach to lamina?

A

Yes. They must to survive apoptosis signals.

40
Q

Why do somatic cells have a finite replicative potential?

A

Because of a lack of telomerase activity. Telomeres shorten with each replication cycle.

41
Q

senescence

A

As telomeres shorten, chromosomal ends become unprotected, leading to cell cycle arrest.

42
Q

How do cancer cells maintain replicative potential?

A

Normally, telomerase expression is largely repressed in postembryonic cell lineages. Cancer cells are able to maintain the expression of telomerase for continued telomerase activity.

43
Q

intravasion

A

From cell into a capillary or lymph vessel

44
Q

extravasion

A

From capillary or lymph vessel into cell

45
Q

How is success rate for each step in metastasis?

A

slow

46
Q

What must new tumors in new locations do?

A

Recruit a blood supply and recruit surrounding cells to create a “niche”

47
Q

Epithelial-mesenchymal transition (EMT)

A

Shutdown of E-cadherin expression enables cancer cells to extricate themselves from the keratinocyte neighbors in the epidermis, while its replacement by expression of N-cadherin allows these tumor cells to interact with mesenchymal cells

48
Q

How are normal epithelial cells kept in place?

A

By cell-cell and cell-ECM interactions

49
Q

What do cancer cells do to cell-cell and cell-ECM interactions?

A

They alter these interactions via changes in gene expression. For example, they alter cell-cell adhesion molecules (CAMs), by losing E-cadherin and gaining N-cadherin.

50
Q

angiogenesis

A

Growth of new blood vessels from pre-existing vessels

51
Q

Why do tumors rely on angiogenesis?

A

They increase in size and need new blood vessels to supply all cells with oxygen and nutrients.

52
Q

How do cancer cells respond to hypoxia?

A

They release factors that stimulate the proliferation of endothelial cells.

53
Q

VEGF

A

Positive factor for angiogenesis

54
Q

How can vascularization be suppressed?

A

By a VEGF receptor inhibitor